Literature DB >> 11836331

An exon splice enhancer mutation causes autosomal dominant GH deficiency.

Chanda T Moseley1, Primus E Mullis, Melissa A Prince, John A Phillips.   

Abstract

Familial isolated GH deficiency type II (IGHD II) is caused, in some cases, by heterogeneous IVS3 mutations that affect GH mRNA splicing. We report here our finding an A-->G transition of the fifth base of exon 3 (E3+ 5 A-->G) in affected individuals from an IGHD II family. This mutation disrupts a (GAA)(n) exon splice enhancer (ESE) motif immediately following the weak IVS2 3' splice site. The mutation also destroys an MboII site used to demonstrate heterozygosity in all affected family members. To determine the effect of ESE mutations on GH mRNA processing, GH(3) cells were transfected with expression constructs containing the normal ESE, +5 A-->G, or other ESE mutations, and cDNAs derived from the resulting GH mRNAs were sequenced. All ESE mutations studied reduced activation of the IVS2 3' splice site and caused either partial E3 skipping, due to activation of an E3+ 45 cryptic 3' splice site, or complete E3 skipping. Partial or complete E3 skipping led to loss of the codons for amino acids 32-46 or 32-71, respectively, of the mature GH protein. Our data indicate that the E3+ 5 A-->G mutation causes IGHD II because it perturbs an ESE required for GH splicing.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836331     DOI: 10.1210/jcem.87.2.8236

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  33 in total

1.  Missense mutations in hMLH1 and hMSH2 are associated with exonic splicing enhancers.

Authors:  Ivan P Gorlov; Olga Y Gorlova; Marsha L Frazier; Christopher I Amos
Journal:  Am J Hum Genet       Date:  2003-10-01       Impact factor: 11.025

2.  BRCA2 T2722R is a deleterious allele that causes exon skipping.

Authors:  James D Fackenthal; Luca Cartegni; Adrian R Krainer; Olufunmilayo I Olopade
Journal:  Am J Hum Genet       Date:  2002-07-19       Impact factor: 11.025

Review 3.  Regulation of alternative RNA splicing by exon definition and exon sequences in viral and mammalian gene expression.

Authors:  Zhi-Ming Zheng
Journal:  J Biomed Sci       Date:  2004 May-Jun       Impact factor: 8.410

Review 4.  Growth hormone and IGF-1.

Authors:  Roberto Salvatori
Journal:  Rev Endocr Metab Disord       Date:  2004-03       Impact factor: 6.514

5.  Synonymous SNPs provide evidence for selective constraint on human exonic splicing enhancers.

Authors:  David B Carlini; Jordan E Genut
Journal:  J Mol Evol       Date:  2005-11-30       Impact factor: 2.395

6.  hnRNP H enhances skipping of a nonfunctional exon P3A in CHRNA1 and a mutation disrupting its binding causes congenital myasthenic syndrome.

Authors:  Akio Masuda; Xin-Ming Shen; Mikako Ito; Tohru Matsuura; Andrew G Engel; Kinji Ohno
Journal:  Hum Mol Genet       Date:  2008-09-20       Impact factor: 6.150

7.  Toward gene therapy for growth hormone deficiency via salivary gland expression of growth hormone.

Authors:  G Z Racz; C Zheng; C M Goldsmith; B J Baum; N X Cawley
Journal:  Oral Dis       Date:  2014-01-13       Impact factor: 3.511

8.  Combined effect of mutations of the GH1 gene and its proximal promoter region in a child with growth hormone neurosecretory dysfunction (GHND).

Authors:  Andrea Paola Rojas-Gil; Panos G Ziros; Efthymios Kanetsis; Vassiliki Papathanassopoulou; Nikoleta M Nikolakopoulou; Kai He; Stuart J Frank; Athanasios G Papavassiliou; Bessie E Spiliotis
Journal:  J Mol Med (Berl)       Date:  2007-05-04       Impact factor: 4.599

9.  Genomic features defining exonic variants that modulate splicing.

Authors:  Adam Woolfe; James C Mullikin; Laura Elnitski
Journal:  Genome Biol       Date:  2010-02-16       Impact factor: 13.583

10.  Disruption of exon definition produces a dominant-negative growth hormone isoform that causes somatotroph death and IGHD II.

Authors:  Robin C C Ryther; Lindsay M McGuinness; John A Phillips; Chanda T Moseley; Charalambos B Magoulas; Iain C A F Robinson; James G Patton
Journal:  Hum Genet       Date:  2003-04-29       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.